Such complexity necessitates precise therapeutic targeting strategies, whether for inhibiting USP30 to curb HCC progression or enhancing its activity to mitigate cerebral ischemia-reperfusion injury. The gene discussed is USP30; the disease is hepatocellular carcinoma.